Le Lézard
Classified in: Health
Subject: SVY

Hearing Aids Market - Forecast to 2022 for the $9.7 Billion Market with Sonova, William Demant, and GN Store Nord Dominating


DUBLIN, November 20, 2017 /PRNewswire/ --

The "Hearing Aids Market - Forecast to 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The global hearing aids market is projected to reach USD 9.78 Billion by 2022 from USD 6.97 Billion in 2017, at a CAGR of 7.0%. Factors such as high prevalence of hearing loss, rising geriatric population, and technological advancements in hearing aids are driving the global market.

This report segments the hearing aids market by product, type of hearing loss, patient type, and region. Based on product, the market is segmented into hearing aid devices and hearing implants. The hearing aid devices segment is expected to account for the largest share of the global market in 2017.

Based on the patient type, the market is segmented into adult patients and pediatric patients. The adult patients segment is expected to register the highest CAGR during the forecast period. The high prevalence of hearing loss in the adult population with growing age is driving the growth of this segment.

In 2017, Europe is expected to dominate the market, followed by North America. The high growth of the market is attributed to growing aging population and high prevalence of hearing loss in the region.

While Europe is expected to dominate the market in 2017, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to the high prevalence of hearing loss, availability of technologically advanced hearing aids, growth in the aging population, and increasing initiatives by companies to expand in these emerging economies. While the hearing aids market presents significant growth opportunities, market growth may be hindered due to the high cost of hearing aids and the low penetration of these devices.

The hearing aids market is dominated by big players such as Sonova (Switzerland), William Demant (Denmark), and GN Store Nord (Denmark) with the presence of several small players as well.

Key Topics Covered:
 
1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Hearing Aids Market, By Product

7 Hearing Aids Market, By Type of Hearing Loss

8 Hearing Aids Market, By Patient Type

9 Hearing Aids Market, By Region

10 Competitive Landscape

11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/rqh7sl/hearing_aids

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....

at 16:05
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December...

at 16:05
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial...

at 16:05
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023...



News published on and distributed by: